##common.pageHeaderLogo.altText##
DOI:
https://doi.org/10.57187/4747

Original article

Vol. 156 No. 11 (2026)

Cannabis-based product use in multiple sclerosis: a Swiss nationwide, registry-based observational study

Cite this as:
Swiss Med Wkly. 2026;156:4747
Published
12.11.2026

Summary

BACKGROUND: Cannabis-based products are commonly used to manage multiple sclerosis (MS) symptoms such as spasticity and pain. However, the prevalence of cannabis-based product use, types of products used and factors associated with use remain unexplored in the Swiss MS population.

OBJECTIVE: To estimate the prevalence of cannabis-based product use, identify factors associated with use and characterise use patterns among people with MS enrolled in the Swiss Multiple Sclerosis Registry (SMSR). Additionally, we explored trends in cannabis-based product types, prescription status and insurance reimbursement over time.

METHODS: This exploratory observational study analysed self-reported data collected between 2016 and 2024. Prevalence estimates and associated factors were assessed using descriptive statistics and multivariable logistic regression on participants’ baseline responses. Follow-up data from cannabis-based product users were analysed descriptively to evaluate temporal trends.

RESULTS: Of the 2193 participants, 330 (14.4%) reported current cannabis-based product use at baseline. Use varied by year of baseline questionnaire completion, ranging from 12.2% in 2016 to 25.6% in 2022. Cannabis-based product use was positively associated with reporting five or more symptoms (odds ratio [OR]:  2.41, 95% confidence interval [CI]: 1.19–5.24), presence of dysphagia (OR:  2.02, 95% CI: 1.27–3.17), spasms (OR: 1.59, 95% CI: 1.13–2.23), pain (OR:  1.48, 95% CI: 1.07–2.05) and greater gait disability (OR:  2.05, 95% CI: 1.39–3.01 for moderate; OR:  2.76, 95% CI: 1.56–4.85 for severe vs mild). Male sex (OR:  1.44, 95% CI: 1.06–1.96) was associated with higher odds of cannabis-based product use, while older age (OR:  0.98 per year, 95% CI: 0.96–0.99) and use of disease-modifying therapies (OR:  0.68, 95% CI: 0.49–0.95) were associated with lower odds. Follow-up data from 469 cannabis-based product users, providing 876 responses, showed cannabidiol was the most frequently used product between 2018 and 2022 but declined from 40% of reported use in 2019–2020 to 25% in 2023. In contrast, nabiximols use increased from 20% in 2018 to 30% in 2023, becoming the most commonly used product. The proportion of prescribed cannabis-based products rose from approximately 30% to 40%, while insurance reimbursement increased from 76% to 93% over the follow-up period.

CONCLUSIONS: Cannabis-based product use among people with MS exceeded rates seen in the general population in Switzerland. Higher symptom burden and greater disability may be key drivers of use. Increasing prescription and reimbursement rates over time suggest a shift towards more regulated, medically supervised use, likely influenced by evolving policy.

References

  1. 1. Yadav V, Bever C, Bowen J, Bowling A, Weinstock-Guttman B, Cameron M, et al. Summary of evidence-based guideline: complementary and alternative medicine in multiple sclerosis: report of the guideline development subcommittee of the American Academy of Neurology. Neurology. 2014 Mar 25;82(12):1083-1092. doi:10.1212/WNL.0000000000000250
  2. 2. Torres-Moreno MC, Papaseit E, Torrens M, Farré M. Assessment of Efficacy and Tolerability of Medicinal Cannabinoids in Patients With Multiple Sclerosis. JAMA Network Open. 2018 Oct 12;1(6):e183485. doi:10.1001/jamanetworkopen.2018.3485
  3. 3. Nielsen S, Germanos R, Weier M, Pollard J, Degenhardt L, Hall W, et al. The use of cannabis and cannabinoids in treating symptoms of multiple sclerosis: a systematic review of reviews. Current Neurology and Neuroscience Reports. 2018 Feb;18(2):8. doi:10.1007/s11910-018-0814-x
  4. 4. Gustavsen S, Søndergaard HB, Andresen SR, Magyari M, Sørensen PS, Sellebjerg F, et al. Illegal cannabis use is common among Danes with multiple sclerosis. Multiple Sclerosis and Related Disorders. 2019 Aug;33:5-12. doi:10.1016/j.msard.2019.05.008
  5. 5. Sacco R, Riccitelli GC, Disanto G, Bogousslavsky J, Cavelti A, Czell D, et al. Effectiveness, Safety and Patients' Satisfaction of Nabiximols (Sativex®) on Multiple Sclerosis Spasticity and Related Symptoms in a Swiss Multicenter Study. Journal of Clinical Medicine. 2024 May 14;13(10):2907. doi:10.3390/jcm13102907
  6. 6. Rice J, Hildebrand A, Spain R, Senders A, Silbermann E, Wooliscroft L, et al. A cross-sectional survey of cannabis use by people with MS in Oregon and Southwest Washington. Multiple Sclerosis and Related Disorders. 2021 Oct;55:103172. doi:10.1016/j.msard.2021.103172
  7. 7. AlHabil Y, Saadeddin L, Ishkirat H, Alqam M, Hossoon O, Hameedi S, et al. Assessing the role of cannabis in managing spasticity in multiple sclerosis: a systematic review and meta-analysis. Clinical Therapeutics. 2026 Jan;48(1):13-21. doi:10.1016/j.clinthera.2025.07.009
  8. 8. Abuhasira R, Shbiro L, Landschaft Y. Medical use of cannabis and cannabinoids containing products – Regulations in Europe and North America. European Journal of Internal Medicine. 2018 Mar;49:2-6. doi:10.1016/j.ejim.2018.01.001
  9. 9. Sativex®, Spray zur Anwendung in der Mundhöhle (cannabis sativae folii cum flore extractum spissum) [Internet]. Swissmedic. Available from: https://www.swissmedic.ch/swissmedic/de/home/humanarzneimittel/authorisations/new-medicines/sativex---spray-zur-anwendung-in-der-mundhoehle--cannabis-sativa.html
  10. 10. Federal Office of Public Health (FOPH). Limited medical use of banned narcotics [Internet]. Available from: https://www.bag.admin.ch/bag/en/home/gesetze-und-bewilligungen/gesuche-bewilligungen/ausnahmebewilligungen-bewilligungen-betmg/ausnahmebewilligungen-verbotene-betaeubungsmittel/ausnahmebewilligungen-beschraenkte-medizinische-anwendung.html
  11. 11. Federal Office of Public Health (FOPH). Medizinische Anwendung von Cannabis [Internet]. doi:10.4414/saez.2018.06542 Available from: https://www.bag.admin.ch/med-anwendung-cannabis#1803655255
  12. 12. Barré T, Testa D, Santos M, Marcellin F, Roux P, Carrieri P, et al. Symptom severity is a major determinant of cannabis‐based products use among people with multiple sclerosis. Journal of Clinical Nursing. 2023 Sep;32(17-18):6460-6473. doi:10.1111/jocn.16674
  13. 13. Clark AJ, Ware MA, Yazer E, Murray TJ, Lynch ME. Patterns of cannabis use among patients with multiple sclerosis. Neurology. 2004 Jun 8;62(11):2098-2100. doi:10.1212/01.wnl.0000127707.07621.72
  14. 14. Rommer PS, König N, Sühnel A, Zettl UK. Coping behavior in multiple sclerosis—complementary and alternative medicine: A cross‐sectional study. CNS Neuroscience & Therapeutics. 2018 Sep;24(9):784-789. doi:10.1111/cns.12857
  15. 15. Schwarz S, Knorr C, Geiger H, Flachenecker P. Complementary and alternative medicine for multiple sclerosis. Multiple Sclerosis Journal. 2008 Sep;14(8):1113-1119. doi:10.1177/1352458508092808
  16. 16. Steinemann N, Kuhle J, Calabrese P, Kesselring J, Disanto G, Merkler D, et al. The Swiss Multiple Sclerosis Registry (SMSR): study protocol of a participatory, nationwide registry to promote epidemiological and patient-centered MS research. BMC Neurology. 2018 Dec;18(1):111. doi:10.1186/s12883-018-1118-0
  17. 17. Puhan MA, Steinemann N, Kamm CP, Müller S, Kuhle J, Kurmann R, et al. A digitally facilitated citizen-science driven approach accelerates participant recruitment and increases study population diversity. Swiss Medical Weekly. 2018 May 16;148(1920):w14623. doi:10.4414/smw.2018.14623
  18. 18. Kaufmann M, Salmen A, Barin L, Puhan MA, Calabrese P, Kamm CP, et al. Development and validation of the self-reported disability status scale (SRDSS) to estimate EDSS-categories. Mult Scler Relat Disord.. 2020;42:102148. doi:0.1016/j.msard.2020.102148
  19. 19. Fox J, Monette G. Generalized Collinearity Diagnostics. J Am Stat Ass. 1992 Mar;87(417):178-183. doi:10.1080/01621459.1992.10475190
  20. 20. Chan A, Silván CV. Evidence-based Management of Multiple Sclerosis Spasticity With Nabiximols Oromucosal Spray in Clinical Practice: A 10-year Recap. Neurodegenerative Disease Management. 2022 Jun;12(3):141-154. doi:10.2217/nmt-2022-0002
  21. 21. Vogel M, Nordt C, Bitar R, Boesch L, Walter M, Seifritz E, et al. Cannabis use in Switzerland 2015–2045: A population survey based model. International Journal of Drug Policy. 2019 Jul;69:55-59. doi:10.1016/j.drugpo.2019.03.008
  22. 22. Been F, Schneider C, Zobel F, Delémont O, Esseiva P. Integrating environmental and self-report data to refine cannabis prevalence estimates in a major urban area of Switzerland. International Journal of Drug Policy. 2016 Oct;36:33-42. doi:10.1016/j.drugpo.2016.06.008
  23. 23. Bertholet N, Marmet S, Wicki M, Gmel G, Studer J. Prevalence, modes of administration and motives for cannabidiol use in young Swiss men. Swiss Medical Weekly. 2021 Dec 20;151(5152):w30054. doi:10.4414/smw.2021.w30054
  24. 24. Gupta S, Fellows K, Weinstock-Guttman B, Hagemeier J, Zivadinov R, Ramanathan M. Marijuana Use by Patients with Multiple Sclerosis. International Journal of MS Care. 2019 Mar 1;21(2):57-62. doi:10.7224/1537-2073.2017-112
  25. 25. Giossi R, Mercenari M, Filippi M, Zanetta C, Antozzi CG, Brambilla L, et al. Unprescribed cannabinoids and multiple sclerosis: a multicenter, cross-sectional, epidemiological study in Lombardy, Italy. Journal of Neurology. 2024 Nov;271(11):7186-7205. doi:10.1007/s00415-024-12472-4
  26. 26. Chong MS, Wolff K, Wise K, Tanton C, Winstock A, Silber E. Cannabis use in patients with multiple sclerosis. Multiple Sclerosis Journal. 2006 Sep;12(5):646-651. doi:10.1177/1352458506070947
  27. 27. Martínez-Rodríguez JE, Munteis E, Carreño M, Blanco Y, Roquer J, Abanades S, et al. Cannabis use in Spanish patients with multiple sclerosis: fulfilment of patients' expectations?. Journal of the Neurological Sciences. 2008 Oct;273(1-2):103-107. doi:10.1016/j.jns.2008.06.037
  28. 28. Chisari CG, Solaro C, Annunziata P, Bergamaschi R, Bianco A, Bonavita S, et al. Nabiximols discontinuation rate in a large population of patients with multiple sclerosis: a 18-month multicentre study. Journal of Neurology, Neurosurgery & Psychiatry. 2020 Sep;91(9):914-920. doi:10.1136/jnnp-2019-322480
  29. 29. Herzog S, Shanahan M, Grimison P, Tran A, Wong N, Lintzeris N, et al. Systematic review of the costs and benefits of prescribed cannabis-based medicines for the management of chronic illness: lessons from multiple sclerosis. PharmacoEconomics. 2018 Jan;36(1):67-78. doi:10.1007/s40273-017-0565-6
  30. 30. Filippini G, Minozzi S, Borrelli F, Cinquini M, Dwan K. Cannabis and cannabinoids for symptomatic treatment for people with multiple sclerosis. Cochrane Database Systematic Reviews. 2022 May 5. doi:10.1002/14651858.CD013444.pub2
  31. 31. Fraguas-Sánchez AI, Torres-Suárez AI. Medical Use of Cannabinoids. Drugs. 2018 Nov;78(16):1665-1703. doi:10.1007/s40265-018-0996-1
  32. 32. Camilleri M, Zheng T. Cannabinoids and the Gastrointestinal Tract. Clinical Gastroenterology and Hepatology. 2023 Dec;21(13):3217-3229. doi:10.1016/j.cgh.2023.07.031
  33. 33. Ablin J, Ste-Marie PA, Schäfer M, Häuser W, Fitzcharles MA. Medical use of cannabis products. Der Schmerz. 2016 Feb;30(1):3-13. doi:10.1007/s00482-015-0083-4
  34. 34. Carotenuto A, Costabile T, De Lucia M, Moccia M, Falco F, Petruzzo M, et al. Predictors of Nabiximols (Sativex®) discontinuation over long-term follow-up: a real-life study. Journal of Neurology. 2020 Jun;267(6):1737-1743. doi:10.1007/s00415-020-09739-x
  35. 35. Hsu M, Shah A, Jordan A, Gold MS, Hill KP. Therapeutic Use of Cannabis and Cannabinoids. JAMA. 2026 Jan 27;335(4):345. doi:10.1001/jama.2025.19433
  36. 36. Buschner M, Heckel N, Dürler P, Engeli EJE, Schneider S, Havelka EM, et al. The Züri Can study: Can regulated cannabis sales promote lower-risk cannabis use? Mini-review and study protocol. International Journal of Drug Policy. 2024 Nov;133:104610. doi:10.1016/j.drugpo.2024.104610
  37. 37. Kirchberger MC. Post-legalization rise in German medical cannabis interest: evidence from Google trends as surrogate marker. Journal of Cannabis Research. 2026 Jan 27;8(1):15. doi:10.1186/s42238-026-00395-y
  38. 38. Eichhorn D, Schaper A, Iwersen-Bergmann S, Ondruschka B, Weber-Papen S, Bernhard M. Cannabis-associated emergencies. Deutsches Ärzteblatt international. 2025 Aug 22;122(17):467. doi:10.3238/arztebl.m2025.0074
  39. 39. Hall W, Stjepanović D, Caulkins J, Lynskey M, Leung J, Campbell G, et al. Public health implications of legalising the production and sale of cannabis for medicinal and recreational use. The Lancet. 2019 Oct;394(10208):1580-1590. doi:10.1016/s0140-6736(19)31789-1
  40. 40. Stanikić M, Braun J, Ajdacic-Gross V, Manjaly Z, Yaldizli Ö, Ineichen BV, et al. Self-reports by persons with multiple sclerosis are an adequate surrogate for healthcare provider data on disease-modifying therapy and multiple sclerosis type. Multiple Sclerosis and Related Disorders. 2023 Dec;80:105097. doi:10.1016/j.msard.2023.105097

Most read articles by the same author(s)

1 2 > >>